• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

    8/8/24 7:00:15 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email

    GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, August 15, 2024, at 8:00 a.m. ET, to report second quarter 2024 financial results and provide business and program updates.

    To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com.

    About BiomX

    BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

    BiomX, Inc.

    Assaf Oron

    +97254-2228901

    [email protected] 



    Primary Logo

    Get the next $PHGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

      NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will present at the Biomed Israel 2025 conference, reviewing the Company's topline Phase 2 results for BX211 in DFO. The conference is being held between May 20 - 22, 2025, in Tel Aviv, Israel. Presentation Details Oral Presentation TitlePrecision Phage Therapy for Chronic Diabetic Foot Infections  SessionImmunology & Inflammation; Reclaim Top Priorities in BioPharma: Driver and Opportunities?  Session T

      5/19/25 10:02:04 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

      In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial The Company will host a conference call and webcast today at 2:00 PM ET NESS ZIONA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage ther

      5/15/25 6:30:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

      NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

      5/8/25 7:00:11 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    SEC Filings

    See more
    • BiomX Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BiomX Inc. (0001739174) (Filer)

      6/9/25 9:23:40 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by BiomX Inc.

      SCHEDULE 13G/A - BiomX Inc. (0001739174) (Subject)

      5/15/25 4:39:25 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by BiomX Inc.

      SCHEDULE 13G - BiomX Inc. (0001739174) (Subject)

      5/15/25 4:29:04 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

      11/16/21 9:23:03 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

      10/19/21 8:36:54 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on BiomX with a new price target

      HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

      10/18/21 12:27:44 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by *Director by Deputization Flynn James E

      4 - BiomX Inc. (0001739174) (Issuer)

      4/23/25 5:49:02 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 4 filed by Director Merril Gregory Louis

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:24:29 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Development Officer Bassan Merav was granted 79,597 shares (SEC Form 4)

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:11:31 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care